| 1.638 0.078 (5%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.18 | 1-year : | 2.55 |
| Resists | First : | 1.87 | Second : | 2.18 |
| Pivot price | 1.48 |
|||
| Supports | First : | 1.42 | Second : | 1.15 |
| MAs | MA(5) : | 1.42 |
MA(20) : | 1.54 |
| MA(100) : | 1.08 |
MA(250) : | 1.42 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 51.4 |
D(3) : | 35.9 |
| RSI | RSI(14): 60.4 |
|||
| 52-week | High : | 2.31 | Low : | 0.68 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PTIX ] has closed below upper band by 22.0%. Bollinger Bands are 59.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.71 - 1.72 | 1.72 - 1.73 |
| Low: | 1.3 - 1.3 | 1.3 - 1.31 |
| Close: | 1.63 - 1.64 | 1.64 - 1.65 |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Wed, 17 Apr 2024
Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit - Yahoo Finance
Tue, 02 Apr 2024
Q4 2023 Protagenic Therapeutics Inc Earnings Call Transcript - GuruFocus.com
Tue, 02 Apr 2024
Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Call Transcript - Yahoo Finance
Mon, 01 Apr 2024
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - Yahoo Finance
Mon, 01 Apr 2024
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023 - InvestorPlace
Wed, 27 Mar 2024
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 21.8 (%) |
| Held by Institutions | 7.9 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.8 % |
| Return on Equity (ttm) | -94.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.43 |
| PEG Ratio | 0 |
| Price to Book value | 1.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|